About Avadel Pharmaceuticals plc
Who We Are: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Oxybate therapy is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients living with narcolepsy. However, currently approved oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night. Our current lead drug candidate, LUMRYZTM (sodium oxybate) extended release for oral suspension (formerly known as FT218), applies our proprietary drug delivery technology to allow for a single bedtime dose, eliminating the need to have a forced awakening during the middle of the night and giving patients the chance for an uninterrupted nights sleep. An extended-release medication sounds like a simple innovation, but it is what has been lacking for 20 years and we believe this will be transformative for people with narcolepsy. For more information, please visit www.avadel.com or check out narcolespydisrupts.com.
What We Do: LUMRYZ has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that LUMRYZ may be clinically superior to a formulation of sodium oxybate already approved by the FDA for the same indication.
The FDA granted a tentative approval to LUMRYZ on July 18, 2022. Tentative approval indicates that LUMRYZ has met all required quality, safety, and efficacy standards necessary for approval in the U.S. FDAs final approval decision for LUMRYZ is pending expiration or other disposition of a patent listed in FDAs Orange Book that expires on June 17, 2023. Avadels market research suggests that LUMRYZ has the potential to command a meaningful share of the multi-billion-dollar narcolepsy treatment market.
We are currently taking steps to accelerate the final approval of LUMRYZ earlier than the expiry of the patent in June 2023, however, in either case, we are gearing up for our full launch now. We cant wait to bring an innovative new treatment option to the narcolepsy community.
How We Work: At Avadel, patients are the reason we exist, and our employees are our greatest competitive advantage our secret sauce. The way we work is as important as the results we achieve. Our employees work together as ONE team and live our Values, which is what makes working at Avadel so special and why we will win for patients. Our ONE Team approach fosters a culture based on being relentless for patients, having confidence with humility, being courageous, taking insights to impact, and togetherness. In everything we do, we live the Avadel Values so we can be our best for our patients, our community and each other.
We are seeking team members who have a passion for making a meaningful impact in the lives of patients. We need individuals who will dive in, roll up their sleeves, and join us in our mission to launch LUMRYZ for the narcolepsy community and be part of building and shaping an exciting future together.
Position Summary:
The Associate Director, Marketing will be a critical member of the brand team responsible for launching LUMRYZ for the treatment of narcolepsy. This position will support the brand team in the execution of the marketing plan to drive awareness and adoption for LUMRYZ for both the HCP and patient/consumer audiences with an emphasis on digital tactical execution. We are looking for a passionate marketer and team player who is a master at details and execution. S/He will support other team members including the VP of Marketing, Sr Director of HCP Marketing, and Sr Director of Patient/Consumer Marketing. This individual will collaborate within the marketing team to contribute to aspects of brand strategy and to the development and execution of the tactics for unbranded and branded HCP and patient campaigns. This is a unique opportunity for an experienced biotech/pharma marketeer to be a core team member on an exciting pharmaceutical launch in the orphan/rare disease area to help people living with narcolepsy as a lifetime, chronic CNS condition.
Essential Functions:
HCP/Patient Marketing Expertise
Agency & Budget Management
Other Key Duties/Responsibilities
Experience and Qualifications:
Other Competencies and Behaviors:
Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. Avadel is committed to equal employment opportunities and non-discrimination in employment. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. Avadel does not discriminate in employment on the basis of race, color, religion, sex, sexual orientation, national origin, age, disability, genetic information, marital status, ancestry, gender, gender identity, pregnancy, status as a covered veteran, or any other characteristic protected by federal, state, and/or local law. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
PI206868640
Nuestras herramientas gratuitas de búsqueda de empleo incluyen alertas para nuevos trabajos, guardado de tus favoritos, trabajo optimizado y ¡mucho más! Simplemente ingrese su correo electrónico a continuación.